Apoorva K. Iyengar

Apoorva K. Iyengar

Auto-generated profile, based on publicly available information

Apoorva K. Iyengar

Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Brain Stimulation
Verified
Journal Article
Closed access
SSStephen L. Schmidt
Stephen L. Schmidt
AIApoorva K. Iyengar
Apoorva K. Iyengar
AFA. Alban Foulser
A. Alban Foulser
MBMichael R. Boyle
Michael R. Boyle
FFFlavio Fröhlich
Flavio Fröhlich

11 September 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CSCassandra N. Spracklen
Cassandra N. Spracklen
AIApoorva K. Iyengar
Apoorva K. Iyengar
SVSwarooparani Vadlamudi
Swarooparani Vadlamudi
CRChelsea K. Raulerson
Chelsea K. Raulerson
AJAnne U. Jackson
Anne U. Jackson
KMKaren L. Mohlke
Karen L. Mohlke
Loci identified in genome-wide association studies (GWAS) can include multiple distinct association signals. We sought to identify the molecular basis of multiple association signals for adiponectin, a hormone involved in glucose regulation secreted almost exclusively from adipose tissue, identified in the Metabolic Syndrome in Men (METSIM) study. With GWAS data for 9,262 men, four loci were significantly associated with adiponectin: ADIPOQ, CDH13, IRS1, and PBRM1. We performed stepwise conditional analyses to identify distinct association signals, a subset of which are also nearly independent (lead variant pairwise r2<0.01). Two loci exhibited allelic heterogeneity, ADIPOQ and CDH13. Of seven association signals at the ADIPOQ locus, two signals colocalized with adipose tissue expression quantitative trait loci (eQTLs) for three transcripts: trait-increasing alleles at one signal were associated with increased ADIPOQ and LINC02043, while trait-increasing alleles at the other signal were associated with decreased ADIPOQ-AS1. In reporter assays, adiponectin-increasing alleles at two signals showed corresponding directions of effect on transcriptional activity. Putative mechanisms for the seven ADIPOQ signals include a missense variant (ADIPOQ G90S), a splice variant, a promoter variant, and four enhancer variants. Of two association signals at the CDH13 locus, the first signal consisted of promoter variants, including the lead adipose tissue eQTL variant for CDH13, while a second signal included a distal intron 1 enhancer variant that showed ~2-fold allelic differences in transcriptional reporter activity. Fine-mapping and experimental validation demonstrated that multiple, distinct association signals at these loci can influence multiple transcripts through multiple molecular mechanisms. Many DNA variants affect common human traits, and distinct variants can have different effects on the function or expression level of the same gene. We identified variants associated with levels of adiponectin, a hormone involved in glucose regulation. Among these variants, we specifically studied the sets of variants located near two genes, ADIPOQ and CDH13, to determine how the variants affect gene expression or function. We focused on sets of variants that can be inherited together but are not always inherited together. Of the variants associated with adiponectin and located near ADIPOQ, one set were also associated with higher expression levels of the protein-coding ADIPOQ gene and a nearby non-coding gene, a second set of variants were associated with lower levels of the ADIPOQ-AS1 antisense gene, and additional variants changed the amino acid sequence or size of the adiponectin protein. Our examples show the benefits of identifying multiple sets of trait-associated variants in the same DNA region. These variants explain more trait variation, help identify genes that affect the trait, and guide studies of gene regulation and biological processes.

30 August 2016 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
SSStephen L. Schmidt
Stephen L. Schmidt
CDChristopher R. Dorsett
Christopher R. Dorsett
AIApoorva K. Iyengar
Apoorva K. Iyengar
FFFlavio Fröhlich
Flavio Fröhlich
Cortical oscillations modulate cellular excitability and facilitate neuronal communication and information processing. Layer 5 pyramidal cells (L5 PYs) drive low-frequency oscillations (<4 Hz) in neocortical networks in vivo. In vitro, individual L5 PYs exhibit subthreshold resonance in the theta band (4–8 Hz). This bandpass filtering of periodic input is mediated by h-current (Ih) and m-current (IM) that selectively suppress low-frequency input. It has remained unclear how these intrinsic properties of cells contribute to the emergent, network oscillation dynamics. To begin to close this gap, we studied the link between cellular and network mechanisms of network resonance driven by L5 PYs. We performed multielectrode array recordings of network activity in slices of medial prefrontal cortex from the Thy1–ChR2–eYFP line and activated the network by temporally patterned optogenetic suprathreshold stimulation. Networks driven by stimulation of L5 PYs exhibited resonance in the theta band. We found that Ih and IM play a role in resonant suprathreshold network response to depolarizing stimuli. The action of Ih in mediating resonance was dependent on synaptic transmission while that of IM was not. These results demonstrate how synergistic interaction of synaptic and intrinsic ion channels contribute to the response of networks driven by L5 PYs.

16 November 2018 in Human Molecular Genetics
Verified
Journal Article
Closed access
JDJames P Davis
James P Davis
SVSwarooparani Vadlamudi
Swarooparani Vadlamudi
TRTamara S Roman
Tamara S Roman
MZMonica Zeynalzadeh
Monica Zeynalzadeh
AIApoorva K Iyengar
Apoorva K Iyengar
KMKaren L Mohlke
Karen L Mohlke
Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are heritable risk factors for cardiovascular disease, yet the molecular mechanisms underlying the majority of blood lipid-associated genome-wide association studies signals remain elusive. One association signal is located in intron 3 of VLDLR; rs3780181-A is a risk allele associated (P <= 2 x 10(-9)) with increased TC and LDL-C. We investigated variants, genes and mechanisms underlying this association signal. We used a functional genetic approach to show that the intronic region spanning rs3780181 exhibited 1.6-7.6-fold enhancer activity in human HepG2 hepatocyte, THP-1 monocyte and Simpson-Golabi-Behmel Syndrome (SGBS) preadipocyte cells and that the rs3780181-A risk allele showed significantly less enhancer activity compared with the G allele, consistent with the direction of an expression quantitative trait locus in liver. In addition, rs3780181 alleles showed differential binding to multiple nuclear proteins, including stronger IRF2 binding to the rs3780181 G allele. We used a CRISPR-cas9 approach to delete 475 and 663 bp of the putative enhancer element in HEK293T kidney cells; compared to expression of mock-edited cell lines, the homozygous enhancer deletion cell lines showed 1.2-fold significantly (P < 0.04) decreased expression of VLDLR, as well as 1.5-fold decreased expression of SMARCA2, located 388 kb away. Together, these results identify an enhancer of VLDLR expression and suggest that altered binding of one or more factors bound to rs3780181 alleles decreases enhancer activity and reduces at least VLDLR expression, leading to increased TC and LDL-C.

17 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AIApoorva K. Iyengar
Apoorva K. Iyengar
XZXue Zou
Xue Zou
JDJian Dai
Jian Dai
RFRhodricia A. Francis
Rhodricia A. Francis
ASAlexias Safi
Alexias Safi
TRTimothy E. Reddy
Timothy E. Reddy
Delayed diagnosis of Mendelian disease substantially prevents early therapeutic intervention that could improve symptoms and prognosis. One major contributing challenge is the functional interpretation of non-coding variants that cause disease by altering splicing and/or gene expression. We identified two siblings with glycogen storage disease (GSD) type IX γ2, both of whom had a classic clinical presentation, enzyme deficiency, and a known pathogenic splice acceptor variant on one allele of PHKG2 . Despite the autosomal recessive nature of the disease, no variant on the second allele was identified by gene panel sequencing. To identify a potential missing second pathogenic variant, we completed whole genome sequencing (WGS) and detected putative deep intronic splicing variant in PHKG2 in both siblings. We confirmed the functional splicing effects of this variant using short-read and long-read RNA-seq on patient blood and a HEK293T cell model in which we installed the variant using CRISPR editing. Using the cell model, we demonstrated multiple biochemical and cellular impacts that are consistent with GSD IX γ2, and a reversal of aberrant splicing using antisense splice-switching oligonucleotides. In doing so, we demonstrate a novel and robust pathway for detecting, validating, and reversing the impacts of novel non-coding causes of rare disease.

20 November 2025 in Genetics in Medicine Open
Verified
Journal Article
Open access
AIApoorva K. Iyengar
Apoorva K. Iyengar
XZXue Zou
Xue Zou
JDJian Dai
Jian Dai
RFRhodricia A. Francis
Rhodricia A. Francis
ASAlexias Safi
Alexias Safi
TRTimothy E. Reddy
Timothy E. Reddy
Delayed diagnosis of Mendelian disease prevents early therapeutic intervention that could improve symptoms and prognosis. One major contributing challenge is functional interpretation of noncoding variants that alter splicing. Here, we aimed to better understand both how splice altering variants contribute to Mendelian disease and how to identify such mechanisms via an instrumental case study of 2 siblings with glycogen storage disease (GSD) IX γ2. The siblings had a classic clinical presentation, enzyme deficiency, and a known pathogenic splice variant on 1 allele of PHKG2 (HGNC:8931). Despite the autosomal recessive nature of the disease, no coding variant on the second allele was identified by targeted sequencing. We evaluated potential noncoding pathogenic variants using genome sequencing and RNA sequencing and created an isogenic model of the candidate variant using CRISPR/Cas9 genome editing. In both siblings, we identified a second variant (NC_000016.10:g.30754626T>G [GRCh38]): a deep intronic variant that caused a 76-bp pseudoexon inclusion in PHKG2. In a HEK293T cell model in which we installed that variant, we confirmed its effects on splicing in addition to multiple biochemical and cellular phenotypes consistent with GSD IX. We then reversed aberrant splicing using antisense oligonucleotide technology. As evidenced by RNA sequencing, population and allelic segregation data, and phenotyping of an isogenic cell culture model of the variant, we concluded that PHKG2 c.556+1069T>G causes GSD IX γ2 and can be targeted using antisense oligonucleotides. This demonstrates a novel and robust pathway for detecting, validating, and reversing the impacts of noncoding causes of rare disease.